J&J Q1 sales jump 9.9% on oncology strength, but STELARA erosion deepens and tariffs hit MedTech

Filed April 22, 2026 · Period ending March 29, 2026 · Compared to 10-Q Apr 23, 2025 · ~2 min read

Key Changes

• high

  Worldwide sales grew 9.9% to $24.1B, driven by 17.8% oncology growth (DARZALEX up 22.5%, CARVYKTI up 62.1%) and 29.3% neuroscience growth including newly acquired CAPLYTA ($270M). Operational growth accelerated from 4.2% to 6.4% year-over-year.

  MD&A: Sales Growth verify on EDGAR →
• high

  STELARA biosimilar erosion worsened to 5.4% drag on worldwide sales (from 4.7% prior year), with STELARA revenue collapsing 59.7% to $656M. New disclosure warns SIMPONI biosimilars may launch H1 2026 in Europe, H2 2026 in U.S.

  MD&A: Immunology & Biosimilar Risk verify on EDGAR →
• high

  MedTech segment margin compressed 340 basis points to 14.3% due to tariffs on cost of goods, Orthopaedics separation costs, and lapping prior-year divestiture gains. Tariffs newly identified as margin pressure driver.

  MD&A: MedTech Margins verify on EDGAR →